Document is current
Any future updates will be listed below
-
Authors
De Solis, Alain J. https://orcid.org/0000-0002-0181-3287
Del Río-Martín, Almudena https://orcid.org/0009-0005-4414-3358
Radermacher, Jan
Chen, Weiyi
Steuernagel, Lukas https://orcid.org/0000-0003-0043-1436
Bauder, Corinna A.
Eggersmann, Fynn R.
Morgan, Donald A.
Cremer, Anna-Lena
Sué, Michael
Germer, Maximilian
Kukat, Christian https://orcid.org/0000-0003-1508-0229
Vollmar, Stefan
Backes, Heiko
Rahmouni, Kamal https://orcid.org/0000-0001-5136-6748
Kloppenburg, Peter https://orcid.org/0000-0002-4554-404X
Brüning, Jens C. https://orcid.org/0000-0002-6619-0092
- License Information
-
More Information
Article History
Received: 13 September 2022
Accepted: 16 January 2024
First Online: 20 February 2024
Competing interests
: J.C.B. is cofounder and shareholder of Cerapeutix and has received research funding through collaborations with Sanofi Aventis and Novo Nordisk, and consultancy fees from Eli Lilly and Company and Novo Nordisk, which did not affect the content of this article. The other authors declare no competing interests.
